DNA repair gene XRCC3 Thr241Met polymorphisms and lung cancer risk: A meta-analysis - 10/04/15
, Gao Yu-fang 2, Sun Jian-ping 3, Ying Zhao-yu 1Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
The X-ray repair cross-complementing group 3 (XRCC3) is a highly suspected candidate gene for cancer susceptibility, and a large amount studies have examined the association of the rs861539 in XRCC3 (Thr241Met) with lung cancer risk in various populations. However, the results remain inconclusive.
Methods |
The electronic database of PubMed, Medline, Embase and CNKI (China National Knowledge Infrastructure) were searched for case-control studies published up to December 05, 2013. A systematic review and meta-analysis was performed to evaluate the relationship between XRCC3 Thr241Met polymorphism and lung cancer risk. Data were extracted and pooled odds ratio (OR) with its 95% confidence intervals (CI) were calculated.
Results |
Total 21 studies, including 6880 lung cancer cases and 8329 controls, were available for meta-analysis. Overall, our results showed that the XRCC3 Thr241Met polymorphism was not associated with risk of lung cancer in all genetic contrast models (P>0.05). Stratified analyses by ethnicity (Asians, Caucasians and mixed population) showed similar results. Additionally, no evidence of publication bias was observed by using the funnel plot.
Conclusions |
There is no clear evidence showing a significant correlation between XRCC3 Thr241Met polymorphism and lung cancer risk in total population and stratified analysis by ethnicity. However, studies assessing the gene-gene interactions should be considered to further estimate this gene variant in lung cancer risk.
Le texte complet de cet article est disponible en PDF.Keywords : XRCC3, Polymorphism, Lung cancer, Association, Meta-analysis
Mots clés : XRCC3, Polymorphisme, Cancer du poumon, Association, Méta-analyse
Plan
Vol 102 - N° 4
P. 332-339 - avril 2015 Retour au numéro
Article précédent
- Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: A retrospective study
- Émilie Soularue, Romain Cohen, Christophe Tournigand, Aziz Zaanan, Christophe Louvet, Jean-Baptiste Bachet, Olivia Hentic, Emmanuelle Samalin, Benoist Chibaudel, Aimery de Gramont, Thierry André, for GERCOR
- Le traitement pré-greffe chez les patients atteints d’un syndrome myélodysplasique de haut risque
- Jordan Gauthier, Gandhi Damaj, Ibrahim Yakoub-Agha
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?